Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

6.83
-0.5000-6.82%
Post-market: 6.75-0.0760-1.11%19:18 EDT
Volume:3.51M
Turnover:24.26M
Market Cap:1.43B
PE:-15.88
High:7.18
Open:7.12
Low:6.77
Close:7.33
Loading ...

BioCryst Pharmaceuticals Inc - Increases Wholesale Acquisition Cost for Orladeyo to $44,484.33 per 28-Day Pack

THOMSON REUTERS
·
08 Jan

BioCryst reports inducement grants under Nasdaq listing rule

TIPRANKS
·
06 Jan

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
06 Jan

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

Simply Wall St.
·
27 Dec 2024

KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says

MT Newswires Live
·
18 Dec 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Dec 2024

RBC Capital Reaffirms Their Buy Rating on BioCryst (BCRX)

TIPRANKS
·
28 Nov 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future

Simply Wall St.
·
26 Nov 2024

BioCryst launches Orladeyo in ireland

TIPRANKS
·
18 Nov 2024

BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator

MT Newswires Live
·
18 Nov 2024

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

GlobeNewswire
·
18 Nov 2024

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire
·
06 Nov 2024

BioCryst Pharmaceuticals Price Target Maintained With a $14.00/Share by Needham

Dow Jones
·
05 Nov 2024

BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays

Dow Jones
·
05 Nov 2024

Evercore ISI Reaffirms Their Buy Rating on BioCryst (BCRX)

TIPRANKS
·
05 Nov 2024

BioCryst Announces Strong Q3 2024 Revenue Growth

TipRanks
·
05 Nov 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Nov 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Nov 2024

BioCryst Pharmaceuticals, Inc. : Barclays Raises Target Price to $8 From $7

THOMSON REUTERS
·
05 Nov 2024

BioCryst price target raised to $8 from $7 at Barclays

TIPRANKS
·
05 Nov 2024